69th DCC Recommends Mandatory Public Disclosure of Suspended and Cancelled Drug Licenses

Vaayath Regulatory Desk | Drugs Consultative Committee, 69th Meeting | Held on 24.06.2026

The Drugs Consultative Committee (DCC), at its 69th meeting held on 24.06.2026, took up an additional agenda item (Agenda No. A-1) addressing a regulatory gap that has quietly undermined drug safety oversight across India: the absence of a uniform, publicly accessible system for tracking license suspensions and cancellations at the state level.

The Problem the DCC Identified

The Committee was informed of a troubling pattern. Certain manufacturers, despite having their original product licenses cancelled, have continued to submit photocopies of these now-invalid licenses to secure procurement orders. This practice exploits a straightforward information gap: buyers and procurement agencies have no easy way to verify whether a license shown to them is still valid.

The DCC traced this gap to two structural issues:

• State/UT Licensing Authorities are not consistently publishing details of license cancellations, suspensions, stop-production orders, or recall alerts on their official websites.
• This information is also not being routinely shared with the Central Drugs Standard Control Organisation (CDSCO), creating a disconnect between State Licensing Authorities (SLAs) and the Centre on regulatory actions and post-market monitoring.

The result is a system where a license cancelled in one state can effectively remain “invisible” to procurement bodies, other regulators, and the public — creating room for exactly the kind of misrepresentation the DCC flagged.

What the DCC Has Recommended

Following detailed deliberation, the DCC issued three recommendations aimed at closing this gap:

In short: Enforcement actions taken by SLAs will no longer stay siloed within the state. Public website disclosure, monthly CDSCO reporting, and standardised NSQ data submission are now expected to work together as a single, traceable regulatory record.

Why This Matters for Manufacturers, Distributors, and Procurement Bodies

For manufacturers

Once implemented, a license cancellation or suspension in one state will be far more visible — to CDSCO, to other SLAs, and to the public. This raises the compliance stakes considerably. Manufacturers with ongoing licensing disputes, show-cause proceedings, or stop-production orders should treat their documentation and regulatory correspondence with heightened care, since these records will increasingly form part of a traceable, cross-referenced regulatory trail rather than a state-siloed file.

For procurement agencies and institutional buyers

Hospitals, government procurement bodies, and distributors will gain a more reliable way to verify license validity before honouring a product license submitted with a tender or purchase order — closing the exact loophole the DCC’s deliberation was built around.

For the regulatory ecosystem

Monthly, standardised NSQ data flow from states to CDSCO strengthens the Centre’s ability to identify patterns — recurring quality failures at a particular facility, or clusters of action within a state — that are difficult to spot when data stays fragmented across 36 states and union territories.

What to Watch For Next

The DCC’s recommendation does not itself prescribe the website format, the data-sharing mechanism with CDSCO, or the NSQ reporting template — these operational details will likely follow through subsequent CDSCO circulars or state-level notifications. Manufacturers and consultants should watch for:

• A prescribed format for monthly NSQ data submission
• Implementation timelines issued to State Licensing Authorities
• Any centralised portal or CDSCO mechanism for aggregating state-level disclosure

Source: Minutes of the 69th meeting of the Drugs Consultative Committee (DCC), held on 24.06.2026 — Additional Agenda No. A-1: “Proposal for public disclosure of all licenses suspended/cancelled by the State Licensing Authorities.”

This article is for general informational purposes and does not constitute regulatory or legal advice. For guidance specific to your facility’s licensing status or compliance posture, reach out to Vaayath Consulting Services Private Limited.